Logo on white.png
EsoCap reports positive topline results from ACESO Phase II trial investigating ESO-101 in eosinophilic esophagitis
December 05, 2023 03:00 ET | EsoCap AG
ESO-101, EsoCap's lead product candidate, consists of a capsule with a rolled-up, thin mucoadhesive film with the anti-inflammatory corticosteroid, mometasone furoateEsoCap's novel targeted delivery...
60 Degrees Pharma Announces Type C Meeting with FDA to Discuss Development of Tafenoquine for Babesiosis, an Emerging Tick-Borne Disease
November 15, 2023 07:29 ET | Sixty Degrees Pharmaceuticals
60 Degrees Pharma (Nasdaq: SXTP) will meet with FDA to discuss its proposed Phase II study on the use of tafenoquine for babesiosis.
60 Degrees Pharma Withdraws COVID Phase IIB IND, Will Resubmit Pending Assessment of Ability to Meet FDA Requirements
September 18, 2023 16:16 ET | Sixty Degrees Pharmaceuticals
Prompted by advice from FDA regarding study design, 60P Australia Pty Ltd, a majority-owned subsidiary of 60 Degrees Pharmaceuticals, has withdrawn its IND for ACLR8-LR, a Phase IIB study of the use...
Hookipa Pharma Logo Square.png
HOOKIPA Pharma Reports Second Quarter 2023 Financial Results and Recent Business Highlights
August 10, 2023 07:01 ET | HOOKIPA Pharma Inc.
HOOKIPA reported positive preliminary Phase 2 data on HB-200 in combination with pembrolizumab in 1st-line setting for advanced head and neck cancerRecruitment ongoing for two Phase 1 clinical trials...
Nemysis Limited Announces Successful IHAT-Gut Trial
February 11, 2023 03:00 ET | Nemysis ltd
DUBLIN, Feb. 11, 2023 (GLOBE NEWSWIRE) -- Nemysis is pleased to announce the publication of the successful findings from the IHAT-Gut trial in iron-deficient anaemic patients (NCT02941081) in the...
IMC Logo.jpg
Immuron Submits IND Application To FDA for Travelan
December 05, 2022 06:00 ET | Immuron Limited
Highlights: Investigational New Drug (IND) application submitted to the U.S. Food and Drug administration (FDA)Plans in place to initiate a Human clinical trial in 60 healthy volunteers in the...
abvc-logo-nasdaq-440x386 (1).png
ABVC BioPharma Provides Vitargus® Update - Phase II Vitargus® Study Protocol Received Thai FDA Approval
November 17, 2022 08:30 ET | ABVC BioPharma, Inc.
FREMONT, CA, Nov. 17, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in...
LiquidPiston X-Engine
LiquidPiston Awarded Phase II Army Contract to Advance Hybrid Electrification for Unmanned Aerial Vehicles (UAVs)
September 13, 2022 09:00 ET | LiquidPiston
BLOOMFIELD, Conn., Sept. 13, 2022 (GLOBE NEWSWIRE) -- LiquidPiston, Inc., the leading innovator of efficient engine technology and hybrid power systems, today announced a $1.7 million Phase II award...
Hookipa Pharma Logo Square.png
HOOKIPA Announces First Patient Enrolled in Phase 2 Trial Evaluating HB-200 and Pembrolizumab for Treatment of Head and Neck Cancer and Reports FDA’s Fast Track Designation
January 18, 2022 07:00 ET | HOOKIPA Pharma Inc.
First patient dosed with HB-200 and pembrolizumab combination for treatment of 1st-line advanced/metastatic head and neck cancer in Phase 2 arm of ongoing Phase 1/2 trial Fast Track Designation...
Earth Science Tech, Inc. (ETST) Executes Phase I Acquisition of RxCompoundStore.com, LLC. and Peaks Curative, LLC.
November 04, 2021 09:00 ET | Earth Science Tech, Inc.
DORAL, FL, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC: ETST) (“ETST” or the “Company”), an innovative biotech company focused in nutraceutical and pharmaceutical fields, and...